Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs TUXARIN ER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
TUXARIN ER contains dextromethorphan, an NMDA receptor antagonist and sigma-1 receptor agonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor. The combination is thought to modulate glutamatergic neurotransmission and enhance dopaminergic and noradrenergic signaling.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
Major depressive disorder (FDA-approved as Auvelity),Treatment-resistant depression (off-label)
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
1 tablet orally every 12 hours; each tablet contains chlorpheniramine maleate 8 mg and phenylephrine HCl 20 mg.
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
The terminal elimination half-life (t1/2) of chlorpheniramine is approximately 14–25 h in adults, allowing twice-daily dosing. Pseudoephedrine has a shorter t1/2 of 5–8 h in normal renal function, but the ER formulation maintains therapeutic levels for 12 h. In renal impairment, pseudoephedrine half-life prolongs significantly, requiring dose adjustment.
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Bupropion is extensively metabolized via CYP2B6 to hydroxybupropion, while dextromethorphan is metabolized primarily by CYP2D6 to dextrorphan. Both are further metabolized by other enzymes.
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
TUXARIN ER is a combination antihistamine/decongestant. The antihistamine component (e.g., chlorpheniramine) is extensively metabolized via CYP450; its metabolites and parent drug (∼68% over 48 h) appear in urine as unchanged drug and metabolites. The decongestant (e.g., pseudoephedrine) is primarily excreted unchanged in urine (∼70–90%) with the remainder metabolized in liver; renal elimination is p H-dependent, with acidic urine increasing excretion. Fecal elimination is negligible (<5%).
38-45%, primarily bound to albumin.
Chlorpheniramine: ∼70% bound to plasma proteins (mainly albumin). Pseudoephedrine: negligible protein binding (<20%).
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
Chlorpheniramine: Vd ≈ 3–5 L/kg, indicating extensive tissue distribution. Pseudoephedrine: Vd ≈ 2.5–3.5 L/kg, consistent with distribution into total body water. Larger Vd suggests sequestration in tissues like lungs and spleen.
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
Chlorpheniramine: Oral bioavailability ∼25–50% due to first-pass metabolism. Pseudoephedrine: Oral bioavailability ∼100% (>90% absorbed, low first-pass effect). The ER formulation maintains equivalent bioavailability with reduced peak concentrations.
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). No specific dose adjustment for mild to moderate impairment; use with caution.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh class C). Use with caution in moderate impairment (Child-Pugh class B); no specific dose adjustment defined.
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
Not recommended for children under 12 years. For children 12 years and older, same as adult dosing: 1 tablet every 12 hours.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
Use with caution due to increased sensitivity to anticholinergic effects (e.g., confusion, urinary retention). Lower initial dose may be considered; avoid use in patients with prostate hypertrophy or glaucoma.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS - Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies. Monitor closely for clinical worsening and emergence of suicidal thoughts and behaviors.
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Increased risk of suicidal thoughts and behaviors; activation of mania/hypomania; seizures (dose-dependent); increased blood pressure; angle-closure glaucoma; serotonin syndrome; hepatotoxicity; neuropsychiatric reactions; allergic and anaphylactic reactions.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
Concurrent use with MAOIs; seizure disorder; history of anorexia nervosa or bulimia; abrupt discontinuation of alcohol, benzodiazepines, or anticonvulsants; known hypersensitivity to any component; use of other bupropion-containing products; concomitant use with linezolid or methylene blue.
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
Avoid alcohol and grapefruit juice. Grapefruit juice may inhibit CYP3A4 metabolism of triprolidine, increasing its levels. High-tyramine foods (e.g., aged cheeses, cured meats) may interact with pseudoephedrine, increasing pressor effects. Take with or without food; food may reduce GI irritation but does not affect absorption.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
TUXARIN ER contains chlorpheniramine and pseudoephedrine. Chlorpheniramine is an antihistamine classified as FDA Pregnancy Category B; animal studies show no risk but no adequate human studies. Pseudoephedrine is FDA Pregnancy Category C; in first trimester, case-control studies suggest a possible association with gastroschisis (odds ratio ~1.8-2.2). After 32 weeks, use may cause premature uterine contractions or fetal tachycardia. Avoid in third trimester due to risk of neonatal irritability and respiratory depression.
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Chlorpheniramine is excreted into breast milk in small amounts (M/P ratio not established). Pseudoephedrine is excreted into breast milk; M/P ratio approximately 3. Initial data indicate pseudoephedrine may reduce milk production by up to 24% with single doses. Use with caution; avoid in cases of established lactation insufficiency. American Academy of Pediatrics considers both drugs compatible with breastfeeding but may cause irritability in infants.
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
No formal dose adjustments established for pregnancy. However, increased plasma volume and renal clearance in pregnancy may reduce pseudoephedrine levels; monitor clinical response. Avoid extended-release formulations if rapid BP fluctuations are a concern. Consider using the lowest effective dose for shortest duration.
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
TUXARIN ER is a fixed-dose combination of pseudoephedrine (120 mg) and triprolidine (2.5 mg) in an extended-release formulation. The delayed-release component may reduce dosing frequency to every 12 hours. Monitor for CNS stimulation; avoid in severe hypertension or coronary artery disease. Use caution in elderly due to anticholinergic effects (triprolidine).
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
Do not crush or chew the tablet; swallow whole with a full glass of water.,Take every 12 hours; do not exceed 2 tablets in 24 hours.,Avoid driving or operating heavy machinery until you know how this medication affects you.,Notify your doctor if you have high blood pressure, heart disease, glaucoma, or urinary retention.,Do not use with other products containing antihistamines or decongestants.,Stop use and seek medical attention if you experience chest pain, rapid heartbeat, or severe dizziness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs TUXARIN ER, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. TUXARIN ER is a Antitussive/decongestant combination that works by TUXARIN ER contains dextromethorphan, an NMDA receptor antagonist and sigma-1 receptor agonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor. The combination is thought to modulate glutamatergic neurotransmission and enhance dopaminergic and noradrenergic signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and TUXARIN ER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of TUXARIN ER is: 1 tablet orally every 12 hours; each tablet contains chlorpheniramine maleate 8 mg and phenylephrine HCl 20 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and TUXARIN ER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. TUXARIN ER is classified as Category C. TUXARIN ER contains chlorpheniramine and pseudoephedrine. Chlorpheniramine is an antihistamine classified as FDA Pregnancy Category B; animal studies show no risk but no adequate h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.